CXCR3型
CD8型
外周血单个核细胞
免疫系统
流式细胞术
免疫学
T细胞
细胞毒性T细胞
免疫失调
医学
质量细胞仪
生物
表型
体外
趋化因子
生物化学
趋化因子受体
基因
作者
Lulu Zhang,Fang Du,Qiqi Jin,Lishan Sun,Boqian Wang,Ziyang Tan,Xinyu Meng,Baozhen Huang,Yifan Zhan,Wenqiong Su,Rui Song,Chunyan Wu,Luonan Chen,Xiaoxiang Chen,Yiyang Li
标识
DOI:10.1002/advs.202300123
摘要
Abstract Systemic Lupus Erythematosus (SLE) etiopathogenesis highlights the contributions of overproduction of CD4 + T cells and loss of immune tolerance. However, the involvement of CD8 + T cells in SLE pathology and disease progression remains unclear. Here, the comprehensive immune cell dysregulation in total 263 clinical peripheral blood samples composed of active SLE (aSLE), remission SLE (rSLE) and healthy controls (HCs) is investigated via mass cytometry, flow cytometry and single‐cell RNA sequencing. This is observed that CD8 + CD27 + CXCR3 − T cells are increased in rSLE compare to aSLE. Meanwhile, the effector function of CD8 + CD27 + CXCR3 − T cells are overactive in aSLE compare to HCs and rSLE, and are positively associated with clinical SLE activity. In addition, the response of peripheral blood mononuclear cells (PBMCs) is monitored to interleukin‐2 stimulation in aSLE and rSLE to construct dynamic network biomarker (DNB) model. It is demonstrated that DNB score‐related parameters can faithfully predict the remission of aSLE and the flares of rSLE. The abundance and functional dysregulation of CD8 + CD27 + CXCR3 − T cells can be potential biomarkers for SLE prognosis and concomitant diagnosis. The DNB score with accurate prediction to SLE disease progression can provide clinical treatment suggestions especially for drug dosage determination.
科研通智能强力驱动
Strongly Powered by AbleSci AI